Morgan Stanley
SQZ

Morgan Stanley’s SQZ Biotechnologies Company SQZ Stock Holding History

Morgan Stanley’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,135
Closed -$4.63K – 7850
2023
Q2 		$4.63K Sell
17,135
-282,601
-94% -$160K ﹤0.01% 7002
2023
Q1 		$168K Buy
299,736
+296,460
+9,049% +$218K ﹤0.01% 5788
2022
Q4 		$2.42K Sell
3,276
-10,145
-76% -$22.2K ﹤0.01% 7318
2022
Q3 		$30K Sell
13,421
-23,936
-64% -$71.8K ﹤0.01% 6630
2022
Q2 		$118K Buy
37,357
+17,541
+89% +$63.1K ﹤0.01% 6192
2022
Q1 		$95K Buy
19,816
+8,992
+83% +$57.1K ﹤0.01% 6347
2021
Q4 		$96K Buy
10,824
+4,238
+64% +$51.9K ﹤0.01% 6472
2021
Q3 		$94K Sell
6,586
-157,673
-96% -$2.14M ﹤0.01% 6420
2021
Q2 		$2.37M Buy
164,259
+162,401
+8,741% +$2.12M ﹤0.01% 4503
2021
Q1 		$25K Sell
1,858
-1,726
-48% -$35.1K ﹤0.01% 6651
2020
Q4 		$104K Buy
+3,584
New +$91.5K ﹤0.01% 5896

Other funds holding SQZ

AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley's SQZ Position: Q3 2023 in Review

Morgan Stanley sold out of SQZ Biotechnologies Company (SQZ) in Q3 2023, closing a stake of 17,135 shares — an estimated $4.63K sold.

Morgan Stanley first reported a position in SQZ in Q4 2020 and held it in 11 quarters. The position peaked at $2.37M in Q2 2021. 5 funds tracked by Wall St. Rank hold SQZ as of Q3 2023.

  • Morgan Stanley reported no remaining SQZ Biotechnologies Company position as of Q3 2023 after selling out during the quarter.
  • Morgan Stanley sold 17,135 SQZ Biotechnologies Company shares in Q3 2023, an estimated $4.63K.
  • Morgan Stanley first reported a position in SQZ Biotechnologies Company in Q4 2020 and held it in 11 quarters.
  • Morgan Stanley's SQZ Biotechnologies Company position peaked at $2.37M in Q2 2021.
  • 5 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.